Sep 04,2024

Tempus Announces Real World Data Collaboration with BioNTech

Tempus AI announced a multi-year collaboration with BioNTech SE , a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. This collaboration leverages Tempus’ multimodal datasets in support of BioNTech’s next-generation oncology pipeline. Under this collaboration, Tempus is providing analytical support and computational biology expertise to BioNTech across its comprehensive research and development oncology pipeline. BioNTech will work collaboratively with Tempus to leverage Tempus’ real-world multimodal database to generate novel insights into the biological mechanisms supporting the discovery of new therapies and aiming to enhance the development of BioNTech’s clinical oncology pipeline.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
May 23,2024

Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395

Owkin announced a drug pipeline in oncology and immunology following a global licensing deal with Idorsia to develop and commercialize OKN4395, a dual inhibitor of prostanoid receptors EP2 and EP4. Owkin leverages its AI engines and multimodal patient data to create detailed biological signatures and identify optimal clinical trial conditions. OKN4395, developed over ten years by Idorsia, is expected to be a best-in-class inhibitor targeting complex cancer pathways.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 30,2024

Caris Life Sciences and COTA, Inc. Announce Collaboration to Expand Collective Multi-Modal Data Offering

Caris Life Sciences and COTA, Inc. have announced a collaboration to expand their multi-modal data offerings for biopharmaceutical drug development and patient care in oncology. By combining Caris' extensive genomic, transcriptomic, proteomic, and imaging data with COTA's curated clinical data, the collaboration aims to provide a comprehensive real-world data solution to drive next-generation therapeutic development and advance patient care in cancer treatment. Caris' molecular-rich database, along with COTA's clinical data from over two million cancer patients across various care settings, will offer valuable insights for optimizing cancer treatments and improving patient outcomes.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Apr 17,2024 TOP STORY

COTA Announces Strategic Collaboration with Sanofi to Leverage Real-World Data and AI to Accelerate Cancer Trials

COTA, a leader in real-world data (RWD) and analytics for oncology, has announced a strategic collaboration with Sanofi aimed at accelerating oncology trials, particularly for multiple myeloma, using RWD and artificial intelligence (AI). The collaboration with Sanofi will focus on addressing key questions relevant to multiple myeloma, aiming to deepen understanding of the disease's treatment landscape. The project's potential outcomes could influence future clinical study designs and inform the interpretation of ongoing and future trial results within the current standard of care for multiple myeloma patients.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 12,2024

Aster Insights and Owkin collaborate to accelerate research in breast cancer

Aster Insights (fka M2GEN) and Owkin are excited to announce a collaboration to accelerate key transatlantic research in breast cancer diagnostics. Aster Insights will provide advanced multimodal data for a customized cohort of breast cancer patients utilizing the company’s novel and proprietary Avatar dataset. "The rate of breast cancer diagnosis across the globe is continually rising and too often, patients will relapse after their initial treatment each year. We are excited to be working with Aster Insights to advance breast cancer research and apply AI to multimodal patient data, ultimately helping us find the right treatment for patients faster.", said Dinesh Divakaran, Vice President of Partnerships, North America at Owkin.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 10,2024

NCCN and Flatiron Health Announce Collaboration to Improve Cancer Care Quality with Real-World Data

Flatiron Health has renewed its collaboration with the National Comprehensive Cancer Network (NCCN). Originating in 2014, the partnership established a cloud-based repository of NCCN Member Institution data, known as the NCCN Quality & Outcomes Database. Crystal S. Denlinger, MD, CEO of NCCN, emphasizes the commitment to providing high-quality cancer care worldwide through leveraging data. The renewal aims to further research with real-world data, enhance cancer care quality, and support quality improvement initiatives at participating NCCN Member Institutions. Neal Meropol, MD, VP of Research Oncology at Flatiron Health, highlights the collaboration's role in improving care standards and addressing evidence gaps in cancer treatment.

COLLABORATION PARTNERSHIP

#institution

#rwd

View Analyst & Ambassador Comments
Go to original news
Mar 14,2024

Tempus Contributes De-Identified Cancer Data to Planned Data Enclave

Tempus announced a data contribution of de-identified tumor profiles with limited associated clinical information from more than 3,000 cancer diagnoses to the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). This is a first of its kind contribution to NCI’s planned Data Enclave and will support the NCI’s mission of advancing cancer research by learning from each individual with cancer. These de-identified data files with associated limited clinical information are derived from advanced-stage cancer patients sequenced with Tempus’ signature xT assay. The tumor data and associated limited clinical information will be available for researchers to query through the NCI Data Enclave, which will securely host data files, including genomic sequencing, that were attained in clinical settings. Users will interact indirectly with the NCI Data Enclave through an Application Programming Interface (API), which will receive queries from users and return cohort level summary results. All summary level results returned to the users by the NCI Data Enclave will be openly accessible to the full cancer research community. 

#rwd

View Analyst & Ambassador Comments
Go to original news
Feb 28,2024

How COTA and Komodo Health Combine Real-World Datasets for Better Patient Insights

Healthcare data leaders Komodo Health and COTA join forces to integrate real-world datasets, enhancing the depth of patient insights and accelerating breakthroughs in healthcare. This strategic partnership combines COTA's high-quality oncology data with Komodo's expansive Healthcare Map™, providing Life Sciences researchers with a comprehensive view of cancer patient journeys and outcomes. The integration of COTA's deep clinical cancer information into Komodo's platform facilitates a more profound understanding of patient communities, offering a robust foundation for research. Komodo CEO Arif Nathoo, MD, and COTA CEO Miruna Sasu discussed the transformative potential of this partnership, emphasizing the era of accelerated evidence, improved decision-making, and enhanced patient outcomes.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 08,2024 TOP STORY

ConcertAI and NeoGenomics Announce Collaboration to Advance Hematological Research & Generative AI Solutions at 2024 JP Morgan Conference

ConcertAI and NeoGenomics, Inc., a leading oncology testing services company, announced a broad collaboration to advance large-scale hematological research solution to investigate real-world clinical practice and outcomes in hematological malignancies. Combining ConcertAI’s longitudinal clinical data with NeoGenomics’ comprehensive biomarkers derived from hundreds of hematological tests, the two copmanies are able to establish a robust and definitive real-world evidence (RWE) hematology solution. This is claimed to be the first population-scale hematology data set, which is both large and broad enough to minimize selection bias, to offer an actionable representation of the hematological prevalent disease in the US. The companies will be launching a hematology-focused collaborative version of ConcertAI’s Clinical Trial Optimization solution later in Q1, supporting study design and optimizing all aspects of trial planning, with multiple clinical development initiatives planned.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Jan 08,2024 TOP STORY

Caris Life Sciences and Flatiron Health Partner to Create Transformational Real-World Data Offering

Caris Life Sciences and Flatiron Health announced a partnership to create a multimodal data offering to support and accelerate biopharmaceutical drug development and patient care. Combining the breadth and depth of Caris’ genomic, transcriptomic and imaging database with Flatiron’s longitudinal patient data and clinical outcomes, equips cancer researchers with comprehensive real-world data (RWD) offering at scale to power the next wave of cancer therapeutics. “This opportunity has the potential to create the largest and best-in-class clinical-omics dataset with Whole Exome and Whole Transcriptome sequencing coverage, expanding our opportunity to support biopharma in the preclinical stages of drug discovery and translation.” said Stephanie Reisinger, Senior Vice President and General Manager, Real-World Evidence, Flatiron Health.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Subscribe to RWD